{
  "id": 20842912,
  "title": "CervoMed CEO John Alam buys $152,621 in company stock",
  "url": "https://urgent.news/2026/11/20/cervomed-ceo-john-alam-buys-152-621-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T02:31:00.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/cervomed-ceo-john-alam-buys-152621-in-company-stock-93CH-5040542"
  },
  "original_language": "en",
  "account": "John J. Alam, CEO and President of CervoMed Inc. (NASDAQ:CRVO) and a director, purchased 100,000 shares of the company's stock on November 18, 2026. The acquisition amounted to $152,621, with shares bought at prices between $1.514 and $1.53 per share. Specifically, 23,681 shares were purchased at $1.514 each and 76,319 shares at $1.53 each. Currently, the stock trades at $1.33, down 21% over the past week, and is near its 52-week low of $1.27. InvestingPro analysis indicates the stock is potentially undervalued, and InvestingPro offers 15 additional tips for CRVO. Following these transactions, Mr. Alam now owns 1,584,078 shares, which includes 1,471,578 shares jointly held with his spouse, Dr. Sylvie Gregoire, a Board of Directors member, and 112,500 shares in their Roth IRAs. CervoMed has also reported significant developments, including positive Phase 2a trial results for its drug neflamapimod and a new 50mg oral tablet formulation. These advancements have led H.C. Wainwright to maintain a Buy rating on the stock with a $25.00 price target.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}